Growth Metrics

Jazz Pharmaceuticals (JAZZ) Long-Term Deferred Tax (2016 - 2025)

Historic Long-Term Deferred Tax for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Q3 2025 value amounting to $846.2 million.

  • Jazz Pharmaceuticals' Long-Term Deferred Tax rose 4508.61% to $846.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $846.2 million, marking a year-over-year increase of 4508.61%. This contributed to the annual value of $560.2 million for FY2024, which is 1724.68% up from last year.
  • Jazz Pharmaceuticals' Long-Term Deferred Tax amounted to $846.2 million in Q3 2025, which was up 4508.61% from $602.9 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' Long-Term Deferred Tax's 5-year high stood at $846.2 million during Q3 2025, with a 5-year trough of $258.5 million in Q1 2021.
  • Moreover, its 5-year median value for Long-Term Deferred Tax was $430.1 million (2023), whereas its average is $447.3 million.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first increased by 9.5% in 2022, then skyrocketed by 4743.45% in 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' Long-Term Deferred Tax (Quarter) stood at $311.1 million in 2021, then rose by 20.94% to $376.2 million in 2022, then increased by 27.0% to $477.8 million in 2023, then grew by 17.25% to $560.2 million in 2024, then surged by 51.04% to $846.2 million in 2025.
  • Its Long-Term Deferred Tax stands at $846.2 million for Q3 2025, versus $602.9 million for Q2 2025 and $575.1 million for Q1 2025.